11/18/2026 | Press release | Distributed by Public on 11/18/2026 02:24
Doctors have long been working with a shallow bench when it comes to fungal infections. Relatively few medications are available to them to prescribe to their patients compared to infections caused by bacteria or even viruses.
And with strains of Candida and Aspergillus, among others, developing a resistance to the drugs that are available, that scarcity of treatment options is emerging as an even more pressing concern.
The College of Natural Sciences and Mathematics' Dr. Heather Conti, right, and Dr. Ronald Viola are exploring a new category of drug targeting the fungal genus Candida.
At The University of Toledo's College of Natural Sciences and Mathematics, Dr. Heather Conti and Dr. Ronald Viola are collaborating to mitigate this emerging threat by exploring a new category of drug targeting the fungal genus Candida. Their research, which is supported by more than $215,000 from the National Institute of Allergy and Infectious Diseases, has the potential to significantly improve the prognosis of patients experiencing symptoms that range from superficial to deadly serious.
"For immunocompromised patients, fungal infections can be life-threatening," Viola said. "And as these strains become more drug resistant, even people with intact immune systems are starting to experience life-threatening infections."
Conti's and Viola's collaboration reflects the strong research community at UToledo, which stands out among the top-tier research universities in the country with the prestigious Carnegie R1 Classification. Faculty and student researchers advance scientific discovery in laboratories across the University, with the National Institutes of Health additionally awarding grants supporting explorations of safer opioids, male infertility, Lyme disease and a rare form of epilepsy, among other areas of research, just since August.
A professor in the Department of Molecular, Cellular and Developmental Biology, as well as an associate dean of the College of Natural Sciences and Mathematics, Conti is an expert in the fungal species that the Centers for Disease Control and Prevention attributes with approximately 7,300 deaths, 130,000 hospitalizations and 13 million outpatient visits each year in the United States. Her laboratory specializes in how the body fights Candida albicans, which is responsible for the oral infection commonly known as thrush.
Viola, meanwhile, brings complementary expertise in enzyme-catalyzed reactions to their collaboration as a Distinguished University Professor emeritus in the Department of Chemistry and Biochemistry. Viola also brings a significant body of established research into the biomechanics of an essential enzyme in Candida, which is key to the covalent drug that Conti, Viola and a postdoctoral researcher are exploring inside Wolfe Hall.
Covalent drugs work by binding irreversibly to a targeted molecule - in this case, that essential enzyme in Candida - in contrast to other categories of drugs that rely on weaker, non-covalent bonds to identify and then inhibit a targeted molecule. Although covalent drugs are not new, with medications as common and established as penicillin categorized among them, they are a subject of renewed interest in the world of drug discovery.
And because the covalent-drug mechanism is fundamentally different than that of the drugs currently prescribed for fungal infections, covalent drugs are especially promising as alternatives to the medications losing efficacy against drug-resistant fungal strains.
"Most current anti-fungal drugs work by interfering with what's called cell-wall synthesis," Viola said. "But the drugs we're developing are different in two key ways. First, we have a completely different target in this enzyme we've identified. And second, as covalent drugs, the way they work is a completely different mode of action."
Under the two-year grant through the National Institutes of Health, Viola and Conti will be exploring and optimizing a class of compounds they've identified to develop more potent enzyme inactivators. Their research will establish a foundation for continued research, in line with an opportunity for additional funding under the National Institute of Allergy and Infectious Diseases.
Their research will also establish a foundation toward eventual development of drugs that could save the lives of some of the patients fighting by drug-resistant fungus infections.
"Our research team relies on important contributions from undergraduate and graduate researchers in the College of Natural Sciences and Mathematics," Conti said. "As the threat of fungal infections grows, the hands-on training we provide these students at the bench will help ensure the next generation of clinicians and scientists are well equipped to diagnose and successfully treat these serious infections."